Product Image

Contributor Information

  • Name Michael Tilby
  • Institute The Institute of Cancer Research; Newcastle University

Tool Details

  • Tool name: Anti-Cisplatin modified DNA [CP9/19]
  • Clone: CP9/19
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Host: Rat
  • Cancer type: Chemotherapy; Broadly Applicable
  • Application: ELISA ; FACS ; IHC ; IP ; DB
  • Description: Antibody CP9/19 recognises only the intra-strand cross-links formed by cisplatin between adjacent purines.
  • Immunogen: Cisplatin modified native DNA
  • Isotype: IgG2a
  • Research area: Genetics
  • Myeloma used: Y3.AG.1.2.3

  • For Research Use Only

Target Details

  • Target: Cisplatin modified native DNA
  • Target background: This antibody enables the quantification of cisplatin-induced adducts on DNA. This antibody has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.

Application Details

  • Application: ELISA ; FACS ; IHC ; IP ; DB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15°C to -25°C
  • Shipping conditions: Shipping at 4°C

Documentation

Related Tools

Product Image

Anti-CD6.1 blocking Mab (human) [OX126]

#156624
Product Image

Anti-Urothelium [LBS17]

#151734
Product Image

Anti-PIP2 [PIP2 2C11]

#151237

References

  • •  Powell et al. 2015. Sci Rep. 5:7975. PMID: 25609656.
  • •  3D-DIP-Chip: a microarray-based method to measure genomic DNA damage.
  • •  Kothandapani et al. 2012. Exp Cell Res. 318(16):1973-86. PMID: 22721696.
  • •  Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.
  • •  Kothandapani et al. 2011. J Biol Chem. 286(16):14564-74. PMID: 21357694.
  • •  Novel role of base excision repair in mediating cisplatin cytotoxicity.
  • •  Meczes et al. 2005. Biochem Pharmacol. 70(12):1717-25. PMID: 16259963.
  • •  Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA.
  • •  Deverman et al. 2002. Cell. 111(1):51-62. PMID: 12372300.
  • •  Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage.
  • •  Veal et al. 2001. Clin Cancer Res. 7(8):2205-12. PMID: 11489793.
  • •  Veal et al. 2001. Clin Cancer Res. 7(8):2205-12. PMID: 11489793.
  • •  Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
  • •  Strobeck et al. 2000. Proc Natl Acad Sci U S A. 97(14):7748-53. PMID: 10884406.
  • •  BRG-1 is required for RB-mediated cell cycle arrest.
  • •  Ghazal-Aswad et al. 1999. Ann Oncol. 10(3):329-34. PMID: 10355578.
  • •  Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.
  • •  Welters et al. 1999. Ann Oncol. 10(1):97-103. PMID: 10076728.
  • •  The potential of plantinum-DNA adduct determination in ex vivo treated tumor fragments for the prediction of sensitivity to cisplatin chemotherapy.
  • •  Peng et al. 1997. Br J Cancer. 76(11):1466-73. PMID: 9400943.
  • •  Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
  • •  Cross et al. 1996. Int J Cancer. 66(3):404-8. PMID: 8621265.
  • •  Effect of quercetin on the genotoxic potential of cisplatin.
  • •  Evans et al. 1994. Cancer Res. 54(6):1596-603. PMID: 8137265.
  • •  Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.
  • •  Tilby et al. 1991. Cancer Res. 51(1):123-9. PMID: 1703029.
  • •  Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.